JP MORGAN 2015: AstraZeneca US president on sales and reimbursement
This article was originally published in Scrip
AstraZeneca US president Paul Hudson has a unique perspective on product sales and reimbursement considering he's worked for the company in the UK, Spain and Japan during the past eight years.
You may also be interested in...
Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.